These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9313871)

  • 1. Synthesis and pharmacological properties of ureidomethylcarbamoylphenylketone derivatives. A new potent and subtype-selective nonpeptide CCK-B/gastrin receptor antagonist, S-0509.
    Hagishita S; Murakami Y; Seno K; Kamata S; Haga N; Konoike T; Kanda Y; Kiyama R; Shiota T; Ishihara Y; Ishikawa M; Shimamura M; Abe K; Yoshimura K
    Bioorg Med Chem; 1997 Aug; 5(8):1695-714. PubMed ID: 9313871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo.
    Takinami Y; Yuki H; Nishida A; Akuzawa S; Uchida A; Takemoto Y; Ohta M; Satoh M; Semple G; Miyata K
    Aliment Pharmacol Ther; 1997 Feb; 11(1):113-20. PubMed ID: 9042983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of phenoxyacetic acid derivatives as highly potent antagonists of gastrin/cholecystokinin-B receptors. II.
    Takeda Y; Kawagoe K; Yokomizo A; Yokomizo Y; Hosokami T; Shimoto Y; Tabuchi Y; Ogihara Y; Otsubo R; Honda Y; Yokohama S
    Chem Pharm Bull (Tokyo); 1998 Jun; 46(6):951-61. PubMed ID: 9658573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist.
    Semple G; Ryder H; Rooker DP; Batt AR; Kendrick DA; Szelke M; Ohta M; Satoh M; Nishida A; Akuzawa S; Miyata K
    J Med Chem; 1997 Jan; 40(3):331-41. PubMed ID: 9022799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological properties of the benzodiazepine amidine derivative L-740,093, a cholecystokinin-B/gastrin receptor antagonist with high affinity in vitro and high potency in vivo.
    Patel S; Smith AJ; Chapman KL; Fletcher AE; Kemp JA; Marshall GR; Hargreaves RJ; Ryecroft W; Iversen LL; Iversen SD
    Mol Pharmacol; 1994 Nov; 46(5):943-8. PubMed ID: 7969084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.
    Nishida A; Miyata K; Tsutsumi R; Yuki H; Akuzawa S; Kobayashi A; Kamato T; Ito H; Yamano M; Katuyama Y
    J Pharmacol Exp Ther; 1994 May; 269(2):725-31. PubMed ID: 7910212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective action of a CCK-B/gastrin receptor antagonist, S-0509, on pentagastrin-, peptone meal- and beer-stimulated gastric acid secretion in dogs.
    Sasaki N; Matsuno K; Okabe S
    Aliment Pharmacol Ther; 2000 Apr; 14(4):479-88. PubMed ID: 10759628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent and subtype-selective CCK-B/gastrin receptor antagonists: 2,4-dioxo-1,5-benzodiazepines with a plane of symmetry.
    Hagishita S; Seno K; Kamata S; Haga N; Ishihara Y; Ishikawa M; Shimamura M
    Bioorg Med Chem; 1997 Jul; 5(7):1433-46. PubMed ID: 9377103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of N- and C-terminal substituents on the CCK-B agonist-antagonist pharmacological profile of Boc-Trp-Phg-Asp-Nal-NH2 derivatives.
    Weng JH; Blommaert AG; Moizo L; Bado A; Ducos B; Böhme A; Garbay C; Roques BP
    Bioorg Med Chem; 1996 Apr; 4(4):563-73. PubMed ID: 8735845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-Phenyl-3-ureidobenzazepin-2-ones as cholecystokinin-B receptor antagonists.
    Lowe JA; Hageman DL; Drozda SE; McLean S; Bryce DK; Crawford RT; Zorn S; Morrone J; Bordner J
    J Med Chem; 1994 Oct; 37(22):3789-811. PubMed ID: 7966138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New 1,4-benzodiazepin-2-one derivatives as gastrin/cholecystokinin-B antagonists.
    Satoh M; Kondoh Y; Okamoto Y; Nishida A; Miyata K; Ohta M; Mase T; Murase K
    Chem Pharm Bull (Tokyo); 1995 Dec; 43(12):2159-67. PubMed ID: 8582018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of phenoxyacetic acid derivatives as highly potent antagonists of gastrin/cholecystokinin-B receptors. III.
    Takeda Y; Kawagoe K; Yokomizo A; Yokomizo Y; Hosokami T; Shimoto Y; Tabuchi Y; Ogihara Y; Honda Y; Kawarabayashi K; Iseri M; Yokohama S
    Chem Pharm Bull (Tokyo); 1999 Jun; 47(6):755-71. PubMed ID: 10399834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological properties of ureido-acetamides, new potent and selective non-peptide CCKB/gastrin receptor antagonists.
    Bertrand P; Böhme GA; Durieux C; Guyon C; Capet M; Jeantaud B; Boudeau P; Ducos B; Pendley CE; Martin GE
    Eur J Pharmacol; 1994 Sep; 262(3):233-45. PubMed ID: 7813588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of S-0509, a novel CCKB/gastrin receptor antagonist, on acid secretion and experimental duodenal ulcers in rats.
    Takeuchi K; Hirata T; Yamamoto H; Kunikata T; Ishikawa M; Ishihara Y
    Aliment Pharmacol Ther; 1999 Jan; 13(1):87-96. PubMed ID: 9892884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of antisecretory and antiulcer activity of CR 2945, a new potent and selective gastrin/CCK(B) receptor antagonist.
    Makovec F; Revel L; Letari O; Mennuni L; Impicciatore M
    Eur J Pharmacol; 1999 Mar; 369(1):81-90. PubMed ID: 10204685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisecretory and ulcer healing effects of S-0509, a novel CCK-B/gastrin receptor antagonist, in rats.
    Amagase K; Ikeda K; Okabe S
    Dig Dis Sci; 1999 May; 44(5):879-88. PubMed ID: 10235591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different effects of CCK antagonists on gastric-acid response to CCK and pentagastrin.
    Corwin RL; Smith GP
    Peptides; 1993; 14(2):253-7. PubMed ID: 8483804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of gastrin- and histamine-stimulated gastric acid secretion by gastrin and cholecystokinin antagonists in the rat.
    Hirst BH; Elliott KJ; Ryder H; Szelke M
    Aliment Pharmacol Ther; 1991 Feb; 5(1):31-9. PubMed ID: 1932479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The gastrin/cholecystokinin-B receptor antagonist L-365,260 reduces basal acid secretion and prevents gastrointestinal damage induced by aspirin, ethanol and cysteamine in the rat.
    Pendley CE; Fitzpatrick LR; Ewing RW; Molino BF; Martin GE
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1348-54. PubMed ID: 8510013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. YM022, a potent and selective gastrin/CCK-B receptor antagonist, inhibits peptone meal-induced gastric acid secretion in Heidenhain pouch dogs.
    Yuki H; Nishida A; Miyake A; Ito H; Akuzawa S; Takinami Y; Takemoto Y; Miyata K
    Dig Dis Sci; 1997 Apr; 42(4):707-14. PubMed ID: 9125636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.